Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

idexx laboratories inc. - IDXX

IDXX

Close Chg Chg %
444.72 -7.64 -1.72%

Closed Market

437.08

-7.64 (1.72%)

Volume: 566.72K

Last Updated:

Dec 11, 2024, 4:00 PM EDT

Trade Now

Company Overview: idexx laboratories inc. - IDXX

IDXX Key Data

Open

$449.01

 Day Range

436.86 - 452.83

52 Week Range

398.50 - 583.39

 Market Cap

$36.42B

Shares Outstanding

81.88M

 Public Float

81.07M

Beta

1.37

 Rev. Per Employee

N/A

P/E Ratio

42.91

 EPS

$10.47

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

659.19K

  

IDXX Performance

1 Week
 
 0.32%
 
1 Month
 
 3.84%
 
3 Months
 
 -12.68%
 
1 Year
 
 -19.22%
 
5 Years
 
 72.83%
 

IDXX Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 16
Full Ratings ➔

About idexx laboratories inc. - IDXX

IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy, and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water Quality Products (Water), Livestock, Poultry, and Dairy (LPD), and Other. The CAG segment provides diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment offers innovative testing solutions for easy, rapid, and accurate detection and quantification of various microbiological parameters in water. The LPD segment develops diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve producer efficiency, and to ensure the quality and safety of milk and food. The Other segment is composed of products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983, and is headquartered in Westbrook, ME.

IDXX At a Glance

IDEXX Laboratories, Inc.
One IDEXX Drive
Westbrook, Maine 04092-2040
Phone 1-207-556-0300 Revenue 3.66B
Industry Medical Specialties Net Income 845.04M
Sector Health Technology 2023 Sales Growth 8.72%
Fiscal Year-end 12 / 2024 Employees 11,000
View SEC Filings

IDXX Valuation

P/E Current 42.907
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 55.159
Price to Sales Ratio 12.732
Price to Book Ratio 31.045
Price to Cash Flow Ratio 51.419
Enterprise Value to EBITDA 39.113
Enterprise Value to Sales 12.90
Total Debt to Enterprise Value 0.023

IDXX Efficiency

Revenue/Employee 332,813.909
Income Per Employee 76,822.00
Receivables Turnover 6.914
Total Asset Turnover 1.219

IDXX Liquidity

Current Ratio 1.515
Quick Ratio 1.115
Cash Ratio 0.477

IDXX Profitability

Gross Margin 59.724
Operating Margin 29.842
Pretax Margin 28.986
Net Margin 23.083
Return on Assets 28.137
Return on Equity 80.739
Return on Total Capital 33.114
Return on Invested Capital 46.798

IDXX Capital Structure

Total Debt to Total Equity 71.898
Total Debt to Total Capital 41.826
Total Debt to Total Assets 32.742
Long-Term Debt to Equity 48.672
Long-Term Debt to Total Capital 28.315
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Idexx Laboratories Inc. - IDXX

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
2.71B 3.22B 3.37B 3.66B
Sales Growth
+12.45% +18.79% +4.73% +8.72%
Cost of Goods Sold (COGS) incl D&A
1.14B 1.31B 1.39B 1.47B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
96.00M 104.60M 111.90M 114.91M
Depreciation
86.20M 92.50M 96.90M 101.11M
Amortization of Intangibles
9.80M 12.10M 15.00M 13.80M
COGS Growth
+8.03% +15.60% +5.71% +6.18%
Gross Income
1.57B 1.90B 1.98B 2.19B
Gross Income Growth
+15.89% +21.11% +4.05% +10.51%
Gross Profit Margin
+58.01% +59.14% +58.76% +59.72%
2020 2021 2022 2023 5-year trend
SG&A Expense
874.01M 954.77M 1.10B 1.09B
Research & Development
141.25M 161.01M 254.82M 190.95M
Other SG&A
732.77M 793.76M 849.55M 903.01M
SGA Growth
+7.67% +9.24% +15.67% -0.94%
Other Operating Expense
- (1.46M) (2.20M) (21.00K)
Unusual Expense
- (199.00K) 4.30M (2.80M)
EBIT after Unusual Expense
696.39M 944.05M 879.23M 1.09B
Non Operating Income/Expense
1.42M (8.79M) 23.40M 10.24M
Non-Operating Interest Income
586.00K 434.00K 1.06M 5.63M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
35.83M 32.61M 42.66M 41.58M
Interest Expense Growth
+7.08% -8.98% +30.82% -2.52%
Gross Interest Expense
35.83M 32.61M 42.66M 41.58M
Interest Capitalized
- - - -
-
Pretax Income
661.99M 902.65M 859.97M 1.06B
Pretax Income Growth
+26.76% +36.36% -4.73% +23.40%
Pretax Margin
+24.46% +28.07% +25.54% +28.99%
Income Tax
79.85M 157.81M 180.88M 216.13M
Income Tax - Current - Domestic
90.27M 131.96M 180.63M 231.64M
Income Tax - Current - Foreign
26.30M 29.29M 35.14M 32.80M
Income Tax - Deferred - Domestic
(16.99M) (7.52M) (37.40M) (42.96M)
Income Tax - Deferred - Foreign
(19.73M) 4.09M 2.52M (5.34M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
582.13M 744.84M 679.09M 845.04M
Minority Interest Expense
- - 355.00K (1.00K)
-
Net Income
581.78M 744.85M 679.09M 845.04M
Net Income Growth
+36.02% +28.03% -8.83% +24.44%
Net Margin Growth
+21.49% +23.17% +20.17% +23.08%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
581.78M 744.85M 679.09M 845.04M
Preferred Dividends
- - - -
-
Net Income Available to Common
581.78M 744.85M 679.09M 845.04M
EPS (Basic)
6.817 8.7423 8.1208 10.1731
EPS (Basic) Growth
+37.25% +28.24% -7.11% +25.27%
Basic Shares Outstanding
85.34M 85.20M 83.62M 83.07M
EPS (Diluted)
6.7085 8.6038 8.0271 10.0627
EPS (Diluted) Growth
+37.30% +28.25% -6.70% +25.36%
Diluted Shares Outstanding
86.72M 86.57M 84.60M 83.98M
EBITDA
792.19M 1.05B 988.33M 1.21B
EBITDA Growth
+25.51% +32.92% -6.14% +22.17%
EBITDA Margin
+29.27% +32.75% +29.35% +32.98%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 495.727
Number of Ratings 16 Current Quarters Estimate 2.40
FY Report Date 12 / 2024 Current Year's Estimate 10.456
Last Quarter’s Earnings 2.80 Median PE on CY Estimate N/A
Year Ago Earnings 10.06 Next Fiscal Year Estimate 12.007
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 11 8 12 12
Mean Estimate 2.40 3.00 10.46 12.01
High Estimates 2.47 3.11 10.53 12.26
Low Estimate 2.35 2.86 10.40 11.73
Coefficient of Variance 1.44 2.94 0.39 1.38

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 7 6 5
OVERWEIGHT 1 1 1
HOLD 6 7 6
UNDERWEIGHT 2 2 2
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Idexx Laboratories Inc. - IDXX

Date Name Shares Transaction Value
May 21, 2024 Bruce L. Claflin Director 161 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $540.8 per share 87,068.80
May 9, 2024 Lawrence D. Kingsley Director 609 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 9, 2024 Bruce L. Claflin Director 863 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 9, 2024 Stuart M. Essig Director 609 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 9, 2024 Asha S. Collins Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 9, 2024 Stuart M. Essig Director 1,974 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 9, 2024 Lawrence D. Kingsley Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 9, 2024 Lawrence D. Kingsley Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 9, 2024 Lawrence D. Kingsley Director 84 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 9, 2024 Lawrence D. Kingsley Director 262 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 9, 2024 Lawrence D. Kingsley Director 195 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 9, 2024 Daniel M. Junius Director 609 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 9, 2024 Lawrence D. Kingsley Director 8,883 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 9, 2024 Lawrence D. Kingsley Director 8,801 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 9, 2024 M. Anne Szostak Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 9, 2024 M. Anne Szostak Director 262 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 9, 2024 M. Anne Szostak Director 609 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 9, 2024 M. Anne Szostak Director 6,561 Bona fide gift 0.00
May 9, 2024 M. Anne Szostak Director N/A Bona fide gift 0.00
May 9, 2024 M. Anne Szostak Director 257 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Idexx Laboratories Inc. in the News